Last reviewed · How we verify

NCT06656338: P2-SDBDC

Phase 2 Seattle Dietary Biomarkers Development Center

Completed NA Last updated 13 April 2026
What this trial tests

NA trial testing Higher HEI-2020 diet followed by lower HEI-2020 diet in Healthy Adults in 32 participants. Completed in 27 February 2026.

Timeline
18 March 2025
Primary endpoint
27 February 2026
27 February 2026

Quick facts

Lead sponsorMarian Neuhouser
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposeother
Enrollment32
Start date18 March 2025
Primary completion27 February 2026
Estimated completion27 February 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Marian Neuhouser

Who can join

18 and older, any sex, with Healthy Adults. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Seattle Dietary Biomarker Development Center (S-DBDC) aims to advance the science of measuring dietary intake by identification and validation of dietary biomarkers that improve upon self-reported diet. To accomplish this mission, the Seattle DBDC will carry out controlled feeding studies in healthy human volunteers. Metabolomics assays will be conducted on blood and urine specimens collected during the feeding studies for biomarker identification. Stool samples will be collected and archived.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Adults

Currently open trials in the same condition.

Other Marian Neuhouser trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06656338.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing